Form 4: VYNE Therapeutics CFO's Routine Stock Withholding for Tax Obligations
Insider Transaction Report
VYNE Therapeutics Inc. Chief Financial Officer Tyler Zeronda reported a routine disposition of 3,420 common shares at $1.65 per share to cover tax withholding requirements related to vested restricted stock units.
Summary
- Tyler Zeronda, Chief Financial Officer of VYNE Therapeutics Inc., reported a transaction on June 30, 2025.
- The transaction involved the disposition of 3,420 shares of Common Stock.
- These shares were withheld by VYNE Therapeutics Inc. to satisfy tax withholding requirements associated with the vesting of restricted stock units.
- The price per share for the withheld shares was $1.65.
- Following this transaction, Tyler Zeronda beneficially owns 115,073 shares of Common Stock directly.
Sentiment
Score: 5
Explanation: The document reports a routine, non-discretionary transaction (shares withheld for tax obligations) which is neutral in sentiment and expected for executive compensation structures.
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically the withholding of shares for tax purposes upon the vesting of restricted stock units. Such transactions are common across all industries, including the biotechnology and pharmaceutical sectors where VYNE Therapeutics operates, and are typically non-discretionary events for executives.
Related Party Transactions
- The transaction involves the disposition of shares by a Chief Financial Officer to the issuer (VYNE Therapeutics Inc.) for tax withholding purposes related to vested restricted stock units, which is a standard related-party transaction in executive compensation.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a discretionary sale by the insider.
- Employees: No direct impact beyond the CFO.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of transaction where shares were disposed of for tax withholding. |
| 07/01/2025 | Date the Form 4 was signed by the Attorney-in-Fact. |
Keywords
VYNE Therapeutics, Tyler Zeronda, Form 4, SEC filing, insider transaction, stock withholding, restricted stock units, tax obligations, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.